Pharmaceutical News

RSS

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

10 Feb 2013

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks.

10 Feb 2013

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

UT Southwestern Medical Center scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy.

10 Feb 2013

Single gene therapy session can cure diabetes

Researchers from the Universitat Aut-noma de Barcelona (UAB), led by F-tima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease.

10 Feb 2013

Health law provisions saved seniors $5.7B on Rx drugs

Seniors have saved about $5.7 billion on prescription drugs since January 2011 because of provisions in the 2010 health care law meant to close the Medicare "doughnut hole," the government plans to announce today.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Shire, Impax resolve pending generic Adderall XR litigation

Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006.

10 Feb 2013

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

The Multiple Myeloma Research Foundation (MMRF) today joined the multiple myeloma community in celebrating the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval of Pomalyst (Celgene Corporation, pomalidomide) for the treatment of patients with relapsed and refractory multiple myeloma who no longer respond to currently available treatments.

10 Feb 2013

TGFβ inhibition enhances chemotherapy action against triple negative breast cancer

Due to chemotherapy resistance and a high rate of relapse, triple negative cancers are among the most difficult breast cancers to treat. In this issue of the Journal of Clinical Investigation, researchers led by Carlos Arteaga at Vanderbilt University identified a protein, TGF-β, that is highly expressed in triple negative breast cancer cells after chemotherapy.

10 Feb 2013

Viewpoints: 'Empty budget gestures'; GOP should endorse 'doomsday' sequester; 'Imagined dangers' imperil vaccine successes

President Obama on Tuesday called on Congress to put off -- again -- the start of the "sequester," a series of across-the-board spending cuts that would save $1.2 billion over 10 years.

9 Feb 2013

Older adults with COPD more frequently use benzodiazepines

A popular class of drugs commonly used to treat sleep and mood symptoms continues to be frequently prescribed despite being known to have potentially life-threatening side effects.

9 Feb 2013

TIC10 may improve usefulness of TRAIL protein in cancer therapy

A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

9 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Washington Post examines relationship between counterfeit drugs, rise of drug-resistant TB

The Washington Post examines the emergence of drug-resistant strains of tuberculosis (TB) around the world, writing, "One culprit in the rise of untreatable TB is counterfeit drugs, which can undermine treatment efforts by packing insufficient active ingredients to fully kill off bacteria, breeding new, stronger super-strains of the disease."

7 Feb 2013

Cantor calls for repeal of medical device tax; Bipartisan Senate bill seeks to end generic drug delays

In a speech, the House majority leader criticized the health law but focused his attention on the overhaul's taxes. Meanwhile, the Senate measure would prohibit companies that make brand-name drugs from paying generic manufacturers to keep their products off the market.

7 Feb 2013

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

7 Feb 2013

Innovative drug discovery in Europe supported by Bayer

Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named European Lead Factory, which has been launched to enhance early drug discovery addressing the need for innovative drugs. The new five-year project will create an exceptional small molecule library collection allowing drug discovery on innovative and promising targets from pharma companies and academia.

7 Feb 2013

FluGen's REDEE FLU vaccine protects against both H5N1 and H3N2 strains

Deadly flu viruses, including the H5N1 bird flu and H3N2 swine flu, may have met their match in FluGen's universal vaccine, REDEE FLU.

6 Feb 2013

More than £6M funding awarded to enhance development of biopharmaceuticals

More than £6M of funding has been awarded to enhance the development of biopharmaceuticals. In total £6.5M will fund 12 projects to deliver commercially important results, such as industrial-scale production of antibodies, stem cell preservation at room temperature, biopharmaceutical production using microbes and commercial scale stem cell therapy.

6 Feb 2013

Pharmaceutical News

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

Single gene therapy session can cure diabetes

Health law provisions saved seniors $5.7B on Rx drugs

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Shire, Impax resolve pending generic Adderall XR litigation

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

TGFβ inhibition enhances chemotherapy action against triple negative breast cancer

Viewpoints: 'Empty budget gestures'; GOP should endorse 'doomsday' sequester; 'Imagined dangers' imperil vaccine successes

Older adults with COPD more frequently use benzodiazepines

TIC10 may improve usefulness of TRAIL protein in cancer therapy

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Washington Post examines relationship between counterfeit drugs, rise of drug-resistant TB

Cantor calls for repeal of medical device tax; Bipartisan Senate bill seeks to end generic drug delays

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Innovative drug discovery in Europe supported by Bayer

FluGen's REDEE FLU vaccine protects against both H5N1 and H3N2 strains

More than £6M funding awarded to enhance development of biopharmaceuticals

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News